Objective: Although it has been recommended that serum free thyroxine (FT 4 ) levels should be targeted to middle-upper normal levels during levothyroxine (L-T 4 ) replacement therapy in patients with central hypothyroidism (CeH), the rationale has not been clarified. Methods: A retrospective single-center study enrolled 116 patients with hypothyroidism (CeH, nZ32; total thyroidectomy (Tx), nZ22; primary hypothyroidism (PH), nZ33; and control benign thyroid nodule (C), nZ29). The patients had received L-T 4 therapy at the Kobe University Hospital between 2003 and 2013. They were stratified according to serum FT 4 level (R1.10 or !1.10 ng/dl), and body temperature (BT), serum free triiodothyronine (FT 3 ) levels, FT 3 /FT 4 ratio, and lipid profiles were compared. The effect of GH replacement therapy on thyroid function was also analyzed. Results: FT 3 levels and FT 3 /FT 4 ratios were significantly lower in patients with CeH than in patients with PH (P!0.05) or C (P!0.05). In patients with FT 4 !1.10 ng/dl, BT was significantly lower in patients with CeH (PZ0.002) and Tx (PZ0.005) than in patients with PH, whereas no differences were found in patients with FT 4 R1.10 ng/dl. In patients with CeH, FT 3 levels were higher in those with GH replacement therapy (PZ0.018). Conclusion: In CeH, patients with median-lower normal levels of serum FT 4 exhibited lower serum FT 3 levels and lower BT. These results support the target levels of serum FT 4 as middle-upper normal levels during L-T 4 replacement therapy in patients with CeH.
Introduction
Central hypothyroidism (CeH) is caused by various hypothalamic-pituitary diseases and frequently combined with other deficiencies of pituitary hormones such as adrenocorticotropic hormone (ACTH), growth hormone (GH), and gonadotropins (Gn). The administration of levothyroxine (L-T 4 ) is standard therapy not only for patients with primary hypothyroidism (PH) but also for patients with CeH. However, despite L-T 4 replacement therapy, it has been reported that some of the patients still complain of symptoms related with hypothyroidism and impaired quality of life (QOL) (1, 2, 3) . Generally, serum thyroid-stimulating hormone (TSH) level is used as a marker for dose adjustment of L-T 4 replacement therapy (4, 5, 6) . However, in patients with CeH, TSH secretion does not often accurately reflect the changes in serum free thyroxine (FT 4 ) levels. In patients with CeH, it has been recommended that serum FT 4 levels should be targeted within the middle to upper limit of the reference range during L-T 4 replacement therapy (7, 8) . However, little evidence supports the rationale for these target FT 4 levels (9) .
The replacement therapy of other pituitary hormones may affect the free triiodothyronine (FT 3 )/FT 4 ratio in patients with CeH associated with hypopituitarism. GH replacement therapy promotes peripheral T 4 to T 3 conversion (10, 11) , whereas high-dose glucocorticoid replacement therapy inhibits deiodinase activity (12, 13) , indicating that the status of replacement therapy is also important in determining the FT 3 /FT 4 ratio. Recently, it has been reported that serum FT 3 levels to FT 4 levels ratio (FT 3 /FT 4 ratio) is lower in patients with CeH than in control subjects (C) (14) . In addition, patients who underwent total thyroidectomy (Tx) exhibited relatively lower FT 3 levels compared with FT 4 levels (15, 16) . These results suggest that T 3 secretion from the thyroid gland plays an important role in the regulation of serum FT 3 levels.
To clarify the optimal levels of serum FT 4 during L-T 4 replacement therapy in patients with CeH, we assessed serum FT 3 levels and FT 3 /FT 4 ratio, and the physiological effects of thyroid hormones such as BMI, heart rate (HR), body temperature (BT), and the parameters of lipid metabolism (17) and compared these with those in patients with Tx and PH.
Subjects and methods

Subjects and design
This was a retrospective observational single-center study involving 116 consecutive patients with hypothyroidism (36 men and 80 women; mean age, 56.1G17.4 years) who had been treated with L-T 4 replacement therapy at Kobe University Hospital between 2003 and 2013. These four groups were stratified (FT 4 R1.10, or !1.10 ng/dl) according to the median value (1.10 ng/dl) of the normal range of serum FT 4 levels (0.70-1.48 ng/dl) (FT 4 R1.10 ng/dl group: CeH, nZ12; Tx, nZ14; PH, nZ19; and C, nZ17; FT 4 !1.10 ng/dl group: CeH, nZ20; Tx, nZ8; PH, nZ14; and C, nZ12). The following parameters were compared between these groups; BMI, systolic blood pressure (sBP), diastolic blood pressure (dBP), HR, BT, serum FT 3 level, FT 3 /FT 4 ratio, and lipid profiles (total cholesterol (T-Chol), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), and triglycerides (TG)). All BT measurements were performed at 10 a.m. in the hospital during hospitalization by using an axillary digital thermometer in a single evaluation (Topnic ET-16, TOP Corporation, Tokyo, Japan). In the CeH group, patients who showed organic hypothalamic damage by tumor invasion or treatment including surgery and/or radiotherapy were excluded. In the Tx group, patients with TSH levels !0.4 miu/ml who had received suppression therapy were excluded as previously described (15) . Control subjects were recruited from among patients with nonfunctioning benign thyroid nodules (!20 mm diameter), whose TSH levels were within the reference range (0.35-4.94 miu/ml). Most of the patients in the CeH group had panhypopituitarism as etiology, including GH deficiency (GHD) caused by various pituitary injuries, and some patients received GH replacement therapy. The status of pituitary function, the number of patients who had received pituitary hormone replacement therapy and etiology of CeH, including CeH subgroups, were summarized in Table 1 . The hypothalamic-pituitary-thyroid axis, hypothalamic-pituitary-adrenal axis, and hypothalamic-pituitary-gonadal axis were evaluated as previously described (18) . For the diagnosis of GHD, each patient was subjected to an insulin tolerance test or GH-releasing peptide 2 test. All of the patients in this study were studied after informed consent. 4 and FT 3 levels, and FT 3 /FT 4 ratio were followed by a variance inflation factor analysis. Comparisons between more than two groups were performed by using the ANOVA, followed by Bonferroni's multiple comparison test between each of the two groups. P values !0.05 were considered as statistically significant. Data were analyzed by using the SPSS Software package (Dr SPSS II for Windows, Nankodo Co., Ltd, Japan).
Statistical analysis
Results
Clinical characteristics, clinical parameters, and L-T 4 doses
The clinical characteristics of the patients in the four groups are described in Fig. 1A ). In contrast, serum FT 3 levels were lower in patients with CeH than in those with Tx, PH, or C (CeH; 2.08G0.51 vs Tx; 2.55G 0.51 pg/ml; PZ0.007, vs PH; 2.78G0.40 pg/ml; P!0.001, vs C; 2.80G0.43 pg/ml; P!0.001; Fig. 1B ). In addition, the mean FT 3 /FT 4 ratios were significantly lower in patients 4 GH replacement
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In patients with CeH and PH, the remaining function of TSH secretion from the pituitary, and the T 3 and/or T 4 secretion from the thyroid, which may affect the FT 3 /FT 4 ratio, had to be considered. Therefore, the subjects were stratified according to L-T 4 dose per kilogram of body weight (R1.0 or !1.0 mg/day per kg), and the serum thyroid hormone levels were compared between the groups. The serum FT 4 levels were comparable between patients with CeH and PH, whereas the serum FT 3 levels were lower in patients with CeH than in those with PH, both in the L-T 4 R1.0 and L-T 4 !1.0 mg/day per kg groups (data not shown).
Association between serum thyroid hormone levels and clinical parameters
Next, we analyzed the association between serum thyroid hormone levels and clinical parameters such as HR and BT, which are regulated by thyroid hormone action. In the multiple linear regression analysis, no significant association was observed between the serum thyroid hormone levels and HR (data not shown). Serum FT 3 value was an independent factor associated with BT (bZ1.051, 95% CI 0.012 to 2.089, PZ0.045; Table 3 ). However, no significant association was observed between serum FT 4 levels and BT (bZK2.027, 95% CI K4.146 to 0.093, PZ0.07; Table 3 ).
Therefore, we stratified the subjects according to the median value of the normal range of serum FT 4 levels (R1.10 or !1.10 ng/dl), and analyzed the association between serum thyroid hormone levels and BT. Clinical characteristics are summarized in Table 4 . The dose of L-T 4 was greater in patients with Tx than in those with CeH or PH, both in the FT 4 R1.10 and FT 4 !1.10 ng/dl groups. Intriguingly, in the FT 4 !1.10 ng/dl group, patients with CeH and Tx exhibited lower BT than those with PH (CeH; Table 4 ). These results suggest that the activity of the thyroid hormone is not sufficient in patients with CeH, whose serum FT 4 levels were lower than the median value of the normal range.
We next analyzed whether the decreased BT in patients with CeH was associated with serum FT 3 levels. As shown in Fig. 2 Fig. 2B ). In contrast, in the FT 4 R1.10 ng/dl group, no significant differences in serum FT 3 levels and FT 3 /FT 4 ratios were observed between these groups (FT 3 levels; CeH; 2.48G0.46 vs PH; 2.82G 0.47 pg/ml, Tx; 2.71G0.44 vs PH; 2.82G0.47 pg/ml; Fig. 2D ). Taken together, these data suggest that lower BT in patients with CeH is associated with relatively lower serum FT 3 levels.
CeH patients with GH replacement therapy
To clarify the effect of GH replacement therapy on the pituitary-thyroid axis, serum FT 4 and FT 3 levels, and the dose of L-T 4 in CeH patients with GH replacement therapy (GH (C)) or without (GH (K)) were compared. In the GH (C) group, serum FT 3 levels were significantly higher than those in the GH (K) group (GH (K); 2.01G0.53 vs GH (C); 2.48G0.42 pg/ml; PZ0.018; Fig. 3A) . In contrast, no significant difference in serum FT 4 levels was found between the groups (GH (K); 1.04G0.26 vs GH (C); 1.13G0.26 ng/dl; PZ0.150; Fig. 3B) . Furthermore, the dose of L-T 4 tended to be higher in the GH (C) group than in the GH (K) group (GH (K); 69.4G26.5 vs GH (C); 80.9G36.0 mg/day; PZ0.075; Fig. 3C ).
We also analyzed the influence of obesity, menopause, and other pituitary hormone deficiency on BT or serum thyroid hormone levels in CeH. We stratified the CeH subjects according to BMI (BMI R25 kg/m 2 : nZ15; BMI !25 kg/m 2 : nZ17), the presence or absence of menopause (menopause (K): nZ14; menopause (C): nZ18), ACTH deficiency (ACTH deficiency (K): nZ4; ACTH deficiency (C): nZ28), and hypogonadism (hypogonadism (K): nZ7; hypogonadism (C): nZ25), and compared the following parameters between these groups: BT, serum FT 4 and FT 3 levels, FT 3 /FT 4 ratios, the dose of L-T 4 replacement therapy, and the dose of L-T 4 per kilogram of body weight (Table 5 ). However, no significant differences were observed between these groups.
Discussion
In this study, we demonstrated that patients with CeH, who exhibited median-lower normal levels of serum FT 4 , revealed low BT with relatively low serum FT 3 levels. Although serum FT 4 levels have been recommended to target within the middle to upper limit of the reference range in patients with CeH, few evidences have been shown to support the rationale of this target. Considering that a low BT represents a state of hypothyroid (17) , the relatively lower serum FT 3 levels with decreased BT in the present study suggest that median-lower normal levels of serum FT 4 are not sufficient to maintain normal thyroid hormone action in patients with CeH. We also compared serum FT 3 levels or FT 3 /FT 4 ratios in four different etiologies of hypothyroidism including patients with CeH, Tx, PH, and C simultaneously, and showed that serum FT 3 levels were lower in patients with CeH compared with the other three groups. Physiologically, serum T 4 is secreted by the thyroid grand (w100%), and serum T 3 is derived from both the thyroid gland (20%) and extra-thyroidal tissues, where T 4 is converted to T 3 (80%) (19) . Meanwhile, owing to the lack of TSH stimulation, T 3 produced by the thyroid gland will decrease in patients with CeH, resulting in lower serum FT 3 levels.
Several factors can affect serum FT 3 and FT 4 levels, and the FT 3 /FT 4 ratio in patients with CeH, including other pituitary hormone deficiency, hormone replacement (14) . In particular, GH replacement therapy promotes peripheral T 4 to T 3 conversion (10, 11) . Indeed, in patients with CeH, serum FT 3 levels were higher in subjects with GH replacement therapy than those without it in our study. Coexisting GHD might decrease serum FT 3 levels because of decreased deiodinase acivity (20, 21) . Furthermore, it is well known that high-dose glucocorticoid replacement therapy inhibits deiodinase activity (12, 13) . However, there were few patients who had received such high-dose glucocorticoid treatment in our study and we did not find any differences in serum thyroid hormone levels between CeH patients with and those without ACTH deficiency. In addition, we should consider an influence of Gn on BT in patients with CeH. It has been reported that central estradiol upregulates Brown adipose tissue (BAT) thermogenesis via inactivating hypothalamic AMPK (22) . However, we did not find any differences in BT or serum thyroid hormone levels between CeH patients with and those without menopause and hypogonadism. P values are for the comparisons between all groups by ANOVA, followed by a non-paired t-test between each of the two groups. *P!0.05, **P!0.01, NS, not significant.
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It is also well known that hypothalamic damage can contribute to BT via the autonomic nervous system. However, in our study, patients who might suffer with hypothalamic damage by tumor invasion or treatment including surgery and/or radiotherapy were excluded. Furthermore, it has been reported that obesity is associated with BT or serum thyroid hormone levels (23, 24) . groups by non-paired t-test. *P!0.05, NS, not significant.
Clinical Study Y Hirata and others L-T 4 therapy for central hypothyroidism
173:2
We analyzed the influence of obesity on BT or thyroid parameters in CeH but found no significant differences between CeH patients with and those without obesity. Thyroid hormone is one of the key regulators of thermal homeostasis (25) . T 3 induces uncoupling protein-1 (UCP-1) expression and mitochondrial biogenesis in human adipocytes, and the effects of T 3 on UCP-1 induction are dependent on the thyroid hormone receptor-b (26) . BAT is specialized for energy expenditure through thermogenesis (27) , mediated by UCP-1 expression (28). It is also known that the type 2 iodothyronine deiodinase (DIO2), an important enzyme to convert T 4 to T 3 , is essential for adaptive thermogenesis in BAT (29) . These findings along with our results indicate that BT might be reduced by relatively low serum FT 3 levels through low UCP-1 expression levels in BAT.
The To date, no consensus guidelines on the management of patients with CeH have been established. Several studies have been performed to investigate the optimal dose of L-T 4 in patients with CeH. It has been shown that L-T 4 dose based on body weight and aiming at serum FT 4 levels in the upper reference range is superior to aiming at the middle of normal FT 4 levels (2). In clinical practice, it has been recommended that serum FT 4 levels should be targeted within the middle to upper limit of the reference range in patients with CeH (7, 8, 9) . However, there has been little evidence supporting the target levels in patients with CeH by using clinical markers of hypothyroidism, such as HR, BT, and lipid profiles during L-T 4 replacement therapy. Our results show that median-lower normal levels of serum FT 4 are associated with both low serum FT 3 levels and low BT, suggesting that these parameters could be clinically useful markers in patients with CeH, in addition to serum FT 4 levels. To confirm these findings, further investigations are required based on the other clinical markers such as basal metabolic rate measured by using an expiration gas analyzer or patient well-being assessed by using hypothyroid specific QOL questionnaires.
Our study has several limitations. First, the sample size, especially after stratification, was relatively small. Therefore, we could not exclude coincidental results. However, the association between low serum FT 3 levels and BT in patients with CeH strongly suggests a functional relevance. Second, various L-T 4 doses were used for replacement therapy, suggesting that patients with varied degrees of the remaining function of the pituitary's TSH secretion and the thyroid's T 3 or T 4 secretion were included, which might have affected the FT 3 /FT 4 ratio. Third, although significant differences in serum FT 3 levels and FT 3 /FT 4 ratios were observed in the patients with CeH and FT 4 !1.10 ng/dl, a similar tendency was found in the patients with CeH and FT 4 R1.10 ng/dl, suggesting that the threshold may not be the median-normal value of serum FT 4 . In this aspect, the optimal replacement dose should be considered based on individual conditions. Fourth, several other confounding factors, including DIO2 polymorphism, may influence BT or serum thyroid hormone levels (33) . Finally, the selection bias in each group needs to be considered. In particular, higher serum TSH levels were observed in patients with Tx because of the exclusion of subjects with TSH levels !0.4 miu/ml, in whom TSH suppression therapy for thyroid cancer was performed.
In conclusion, patients with CeH who exhibited medianlower normal levels of serum FT 4 revealed low BT with relatively low serum FT 3 levels. GHD might have contributed to the serum FT 3 attenuation in these patients. These data support the previously recommended target levels of serum FT 4 at the middle to upper limit of the reference range in patients with CeH. It is not known whether the middle-upper normal levels of serum FT 4 would improve low BT and maintain well-being during L-T 4 replacement therapy in patients with CeH. Further large-scale, prospective, interventional studies are needed to determine the optimal replacement therapy in patients with CeH.
